Drug compounding facilities should be allowed to produce products beyond the FDA’s current hard compounding cut-off, which kicks in when a drug immediately drops off the FDA’s drug shortages list. The allowance could be applied to weight-loss drugs and other chronically in-demand medications, legal experts said at the NASP 2024 Annual Meeting & Expo, in Nashville, Tenn.
This extension would leverage 503A and 503B drug compounding facilities as potential avenues for